Assembly Biosciences, Inc. (ASMB) | Investment Case

1. Company Snapshot

1.a. Company Description

Assembly Biosciences, Inc., a clinical-stage biotechnology company, discovers and develops therapeutic candidates for the treatment of hepatitis B virus (HBV) infection in the United States.The company's lead product candidate is Vebicorvir, which as completed Phase 2 clinical trials to treat patients with chronic HBV infection.It is also developing ABI-H3733 that has completed Phase 1a clinical study, and ABI-4334, which is in pre-clinical trials for the treatment of HBV.

The company has collaboration agreements with BeiGene, Ltd.and Arbutus Biopharma Corporation; and Antios Therapeutics, Inc.to evaluate a triple combination treatment in patients with chronic hepatitis B virus infection.

It also has strategic license agreements with Indiana University Research and Technology Corporation; and Door Pharmaceuticals, LLC.The company was formerly known as Ventrus Biosciences, Inc.and changed its name to Assembly Biosciences, Inc.

in June 2014.Assembly Biosciences, Inc.was incorporated in 2005 and is headquartered in South San Francisco, California.

Show Full description

1.b. Last Insights on ASMB

Assembly Biosciences' recent performance was driven by a series of positive developments. The company's upgrade to a Zacks Rank #2 (Buy) reflects growing optimism about its earnings prospects. Additionally, four development candidates are in clinical studies, with data anticipated this year, showcasing the rapid progress of its antiviral pipeline. Recent presentations at the 2025 ESCMID Congress highlighted the promising dosing profile and tolerability of ABI-5366, a novel long-acting helicase-primase inhibitor candidate. Furthermore, the initiation of a Phase 1a clinical study of ABI-6250, an orally bioavailable hepatitis delta virus entry inhibitor candidate, demonstrates the company's commitment to advancing its pipeline.

1.c. Company Highlights

Last Price	35.01
Change Percentage	-0.74%
Open	35.51
Previous Close	35.27
Market Cap ( Millions)	301
Volume	28548
Year High	39.71
Year Low	7.75
M A 50	31.06
M A 200	20.04

FCF Yield	-18.53%
Dividend Yield	0.00%
ROE	-149.01%
Debt / Equity	15.93%
Net Debt / EBIDTA	48.64%
Price To Book	14.81
Price Earnings Ratio	-6.88
Price To FCF	-5.4
Price To sales	12.76
EV / EBITDA	-6.46

2. Transcript Summary

Unfortunately this company is not part of our coverage yet. But as part of your subscription plan you can request it by clicking just below and we'll process.

Request Coverage

3. NewsRoom

Assembly Biosciences, Inc. (NASDAQ:ASMB) Receives $41.25 Consensus PT from Brokerages

Nov -16

Source: defenseworld.net

Assembly Biosciences Reports Third Quarter 2025 Financial Results and Recent Updates

Nov -10

Source: globenewswire.com

Assembly Biosciences Presents Positive Phase 1b Data for Next-Generation Capsid Assembly Modulator ABI-4334 at AASLD The Liver Meeting®

Nov -07

Source: globenewswire.com

Comparing Amphastar Pharmaceuticals (NASDAQ:AMPH) & Assembly Biosciences (NASDAQ:ASMB)

Oct -20

Source: defenseworld.net

Assembly Biosciences Announces Upcoming Investor Conference Participation

Oct -14

Source: globenewswire.com

Assembly Biosciences Announces Upcoming Investor Conference Participation

Oct -14

Source: globenewswire.com

Assembly Biosciences Presents Interim Phase 1b Data for HSV Helicase-Primase Inhibitor Candidate ABI-5366 at the 38th Congress of the International Union Against Sexually Transmitted Infections (IUSTI)- Europe

Oct -10

Source: globenewswire.com

Assembly Biosciences: Positive Data Of ABI-5366 Brings 2 Fall Program Catalysts

Aug -08

Source: seekingalpha.com

4. Business Breakdown

4.a. Revenues by Country

4.b. Revenues by Segment

5. Expected revenues mid-term growth (9.33%)

6. Segments

Novel Therapeutics

Expected Growth: 9.33%

Assembly Biosciences' Novel Therapeutics segment growth of 9.33% is driven by increasing adoption of its microbiome-based therapies, expansion into new indications, and strategic partnerships. The company's proprietary platform and strong pipeline of candidates also contribute to growth, as well as growing demand for innovative treatments in the infectious disease and oncology markets.

7. Detailed Products

HBV Core Inhibitor

A novel class of oral therapeutic agents designed to inhibit the activity of the hepatitis B virus (HBV) core protein, which is essential for the virus's replication.

HBV RNA Destabilizer

A new class of oral therapeutic agents designed to destabilize the hepatitis B virus (HBV) RNA, which is essential for the virus's replication.

HBV cccDNA Inhibitor

A novel class of oral therapeutic agents designed to inhibit the formation of covalently closed circular DNA (cccDNA), which is the viral reservoir that perpetuates chronic hepatitis B infection.

HBV Therapeutic Vaccine

A novel therapeutic vaccine designed to stimulate the immune system to recognize and eliminate hepatitis B virus (HBV)-infected cells.

8. Assembly Biosciences, Inc.'s Porter Forces

Forces Ranking

Threat Of Substitutes

Assembly Biosciences, Inc. has a moderate threat of substitutes due to the availability of alternative treatments for viral diseases and liver diseases.

Bargaining Power Of Customers

Assembly Biosciences, Inc. has a low bargaining power of customers due to the lack of negotiating power of individual customers.

Bargaining Power Of Suppliers

Assembly Biosciences, Inc. has a moderate bargaining power of suppliers due to the availability of multiple suppliers for raw materials and services.

Threat Of New Entrants

Assembly Biosciences, Inc. has a high threat of new entrants due to the attractiveness of the biotechnology industry and the availability of funding for startups.

Intensity Of Rivalry

Assembly Biosciences, Inc. operates in a highly competitive industry with several established players, leading to a high intensity of rivalry.

9. SWOT Analysis

10. Capital Structure

10.a. Balance Sheet

10.b. Weighted Average Cost of capital

	Value
Debt Weight	5.39%
Debt Cost	3.95%
Equity Weight	94.61%
Equity Cost	6.99%
WACC	6.83%
Leverage	5.70%

11. Quality Control: Assembly Biosciences, Inc. passed 6 out of 9 key points

Strong Liquidity

Low Debt

Strong Interest Coverage

Healthy Cash Flow

Operating Efficiency

Strong Return On Equity

Consistent Revenue Growth

Consistent Operating Cash Flow Growth

Margin Improvement

12.a Historical Valuation

12.b Price/Earnings Ratio

12.c Margin Valuation

12.d Peers Valuation

Peers Group Analysis

Fulcrum Therapeutics

A-Score: 5.4/10

Value: 6.8

Growth: 8.0

Quality: 6.4

Yield: 0.0

Momentum: 9.5

Volatility: 1.7

1-Year Total Return ->

Xeris Biopharma

A-Score: 5.2/10

Value: 6.2

Growth: 7.1

Quality: 5.4

Yield: 0.0

Momentum: 10.0

Volatility: 2.7

1-Year Total Return ->

Assembly Biosciences

A-Score: 4.3/10

Value: 6.2

Growth: 3.8

Quality: 4.6

Yield: 0.0

Momentum: 9.0

Volatility: 2.0

1-Year Total Return ->

Actinium Pharmaceuticals

A-Score: 3.7/10

Value: 6.8

Growth: 5.9

Quality: 3.1

Yield: 0.0

Momentum: 5.0

Volatility: 1.3

1-Year Total Return ->

Clearside Biomedical

A-Score: 3.3/10

Value: 8.4

Growth: 3.6

Quality: 6.1

Yield: 0.0

Momentum: 0.5

Volatility: 1.0

1-Year Total Return ->

Cardiff Oncology

A-Score: 3.1/10

Value: 6.6

Growth: 4.1

Quality: 4.6

Yield: 0.0

Momentum: 2.5

Volatility: 0.7

1-Year Total Return ->

Peers Metrics

12.e Scoring ^Insights

12.f DCF ^BETA

Parameters

Short Term Growth

16.25%

Short term Time

10.0

Long-Term Growth

2.00%

WACC

6.83%

Assembly Biosciences, Inc. - US0453962070

1. Company Snapshot

1.a. Company Description

1.b. Last Insights on ASMB

1.c. Company Highlights

Average Growth

Stable Momentum

Average Yield

Earnings Beats

Medium Volatility

Fairly Valued

Revenues Beats

Lower Growth

Strong Momentum

Revenues Miss

Weak Momentum

Average Quality

Earnings Miss

2. Transcript Summary

3. NewsRoom

4. Business Breakdown

4.a. Revenues by Country

4.b. Revenues by Segment

5. Expected revenues mid-term growth (9.33%)

6. Segments

Novel Therapeutics

Expected Growth: 9.33%

7. Detailed Products

HBV Core Inhibitor

HBV RNA Destabilizer

HBV cccDNA Inhibitor

HBV Therapeutic Vaccine

8. Assembly Biosciences, Inc.'s Porter Forces

Forces Ranking

Threat Of Substitutes

Bargaining Power Of Customers

Bargaining Power Of Suppliers

Threat Of New Entrants

Intensity Of Rivalry

9. SWOT Analysis

Strength

Weaknesses

Opportunities

Threats

10. Capital Structure

10.a. Balance Sheet

10.b. Weighted Average Cost of capital

11. Quality Control: Assembly Biosciences, Inc. passed 6 out of 9 key points

12.a Historical Valuation

12.b Price/Earnings Ratio

12.c Margin Valuation

12.d Peers Valuation

Peers Group Analysis

Peers Metrics

12.e Scoring Insights

12.f DCF BETA

Parameters

Short Term Growth

Short term Time

Long-Term Growth

WACC

Target Price

35.01$

Current Price

35.01$

Potential

-0.00%

Expected Cash-Flows

12.e Scoring ^Insights

12.f DCF ^BETA